ATE522507T1 - Montelukast in fester phase - Google Patents

Montelukast in fester phase

Info

Publication number
ATE522507T1
ATE522507T1 AT04765940T AT04765940T ATE522507T1 AT E522507 T1 ATE522507 T1 AT E522507T1 AT 04765940 T AT04765940 T AT 04765940T AT 04765940 T AT04765940 T AT 04765940T AT E522507 T1 ATE522507 T1 AT E522507T1
Authority
AT
Austria
Prior art keywords
montelukast
compound
fixed phase
formula
formulated
Prior art date
Application number
AT04765940T
Other languages
English (en)
Inventor
Arjanne Overeem
Den Heuvel Dennie Van
Original Assignee
Synhton B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE522507(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synhton B V filed Critical Synhton B V
Application granted granted Critical
Publication of ATE522507T1 publication Critical patent/ATE522507T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
AT04765940T 2003-10-10 2004-10-08 Montelukast in fester phase ATE522507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50995703P 2003-10-10 2003-10-10
PCT/EP2004/011430 WO2005040123A1 (en) 2003-10-10 2004-10-08 Solid-state montelukast

Publications (1)

Publication Number Publication Date
ATE522507T1 true ATE522507T1 (de) 2011-09-15

Family

ID=34520017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765940T ATE522507T1 (de) 2003-10-10 2004-10-08 Montelukast in fester phase

Country Status (12)

Country Link
US (1) US7553853B2 (de)
EP (1) EP1678139B1 (de)
JP (2) JP2007508271A (de)
AT (1) ATE522507T1 (de)
AU (1) AU2004283832B2 (de)
CA (1) CA2541994A1 (de)
ES (1) ES2371549T3 (de)
IL (1) IL174758A (de)
NO (1) NO20062098L (de)
PT (1) PT1678139E (de)
WO (1) WO2005040123A1 (de)
ZA (1) ZA200602837B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
PT1678139E (pt) 2003-10-10 2011-11-28 Synhton B V Montelucaste em estado sólido
US20070225325A1 (en) * 2004-01-28 2007-09-27 Pliva-Istrazivanje I Razvoj D.O.O. Solid Forms of Montelukast Acid
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
EP1708708A1 (de) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast-freie säure-polymorphen
EP1760077A1 (de) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Polymorphe Formen vonMontelukast freie Säure
WO2005074893A1 (en) * 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
MXPA06012220A (es) 2004-04-21 2007-07-18 Teva Pharma Procesos para preparar sodio de montelukast.
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
DE602004031678D1 (de) * 2004-07-19 2011-04-14 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
US9149472B2 (en) * 2004-08-31 2015-10-06 Jack William Schultz Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
CA2589936A1 (en) * 2004-11-30 2006-06-08 Medichem S.A. New process for the preparation of a leukotriene antagonist
WO2006064269A2 (en) * 2004-12-17 2006-06-22 Cipla Limited Salts of leukotriene antagonist montelukast
KR20090015186A (ko) * 2005-07-05 2009-02-11 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트의 정제
AR057908A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast e intermediarios del mismo
WO2007069261A1 (en) * 2005-12-13 2007-06-21 Msn Laboratories Limited An improved process for the preparation of montelukast and its pharmaceutically acceptable salts
SI1976522T2 (sl) 2005-12-30 2019-11-29 Krka Tovarna Zdravil D D Novo Mesto Farmacevtski sestavek, ki vsebuje montelukast
EP1803457A1 (de) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmazeutische Zubereitung, welche Montelukast enthält
JP2009526047A (ja) * 2006-02-09 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムの安定な医薬製剤
EP1996552A1 (de) * 2006-03-17 2008-12-03 Synthon B.V. Montelukast-amantadin-salz
EP1886998A1 (de) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
SI22382A (sl) * 2006-10-26 2008-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek za pripravo montelukasta
US8115004B2 (en) * 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
KR20100072295A (ko) * 2007-10-25 2010-06-30 머크 프로스트 캐나다 리미티드 병용 요법
WO2009098271A1 (en) * 2008-02-06 2009-08-13 Farmaprojects, S.A. Process for the purification of montelukast by the preparation of acid addition salts and tert-amylamine salt
CN102046602A (zh) * 2008-04-25 2011-05-04 斯索恩有限公司 制备孟鲁司特中间体的方法
EP2287154A1 (de) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Effiziente Synthese zur Herstellung von Montelukast
KR101445671B1 (ko) 2010-02-26 2014-09-29 도레이 카부시키가이샤 피복 고형 제제
EP2552892A1 (de) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Effiziente synthese zur herstellung von montelukast und neue kristalline form von zwischenprodukten darin
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
JP6488003B2 (ja) 2014-04-25 2019-03-20 アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー 安定なモンテルカスト溶液
EP3846792A4 (de) 2018-09-06 2022-10-12 Innopharmascreen Inc. Verfahren und zusammensetzungen zur behandlung von asthma oder morbus parkinson
CN111307979A (zh) * 2020-03-14 2020-06-19 鲁南制药集团股份有限公司 一种孟鲁司特钠及其制剂的有关物质检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266568A (en) * 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
HUT61980A (en) * 1990-10-12 1993-03-29 Merck Frosst Canada Inc Process for producing saturated hydroxyalkylquinoline acids and pharmaceutical compositions comprising such compounds as active ingredient
EP0480717B1 (de) * 1990-10-12 1998-04-15 Merck Frosst Canada Inc. Ungesättigte Hydroxyalkylchinolinsäuren als Leukotrien-Antagonisten
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW416948B (en) 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
CN1268624C (zh) * 2000-10-20 2006-08-09 伊莱利利公司 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
CN1420113A (zh) * 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
WO2003066598A1 (en) * 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004108679A1 (en) 2003-06-06 2004-12-16 Morepen Laboratories Limited An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form
PT1678139E (pt) 2003-10-10 2011-11-28 Synhton B V Montelucaste em estado sólido
EP1708708A1 (de) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast-freie säure-polymorphen
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor

Also Published As

Publication number Publication date
ES2371549T3 (es) 2012-01-05
US7553853B2 (en) 2009-06-30
EP1678139B1 (de) 2011-08-31
AU2004283832A1 (en) 2005-05-06
CA2541994A1 (en) 2005-05-06
NO20062098L (no) 2006-05-10
EP1678139A1 (de) 2006-07-12
PT1678139E (pt) 2011-11-28
JP2007508271A (ja) 2007-04-05
IL174758A (en) 2012-09-24
IL174758A0 (en) 2006-08-20
WO2005040123A1 (en) 2005-05-06
ZA200602837B (en) 2007-09-26
JP2012072149A (ja) 2012-04-12
AU2004283832B2 (en) 2011-04-07
US20050107426A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
ATE522507T1 (de) Montelukast in fester phase
TW200616976A (en) Pyrimidine derivatives
LUC00155I1 (de)
TW200626558A (en) Indazolone derivatives
MY138941A (en) Aryl-pyridine derivatives
UA94052C2 (uk) Похідні піридазину
DE60144392D1 (de) Antivirale mittel
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
DE60217118D1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
NO20090328L (no) Nye forbindelser 385
BR0317749A (pt) Composto, composição farmacêutica, e, uso de um composto
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
ATE297910T1 (de) Retinoid x rezeptormodulatoren
ME01395B (de) Verfahren zur Herstellung von (1S)-4,5-Dimethoxy-1-(methylaminomethyl)-benzocyclobutan und deren Säureadditionssalze, sowie ihre Verwendung für die Synthese von Ivabradin und deren Säureadditionssalze von pharmazeutischen verträglichen Säure
EP1340755A4 (de) Mittel mit wirkung gegen helicobacter
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
WO2007025880A3 (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
WO2005120516A3 (en) Hiv integrase inhibitors
IS7482A (is) Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf
MX2009003169A (es) Derivados de sulfonamida.
HRP20060023A2 (en) Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties